According to the Complaint, Audentes Therapeutics, Inc. is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases.

This action stems from a proposed transaction announced on December 2, 2019, pursuant to which Audentes Therapeutics, Inc. will be acquired by Astellas Pharma Inc.

On December 2, 2019, Audentes’ Board of Directors caused the Company to enter into an agreement and plan of merger with Astellas.

On December 16, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on February 18, 2020.